NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Key Takeaways NKTR rose 38.2% on investor optimism for rezpeg in atopic dermatitis compared to a rival candidate.Rezpeg met key goals in a phase IIb study for atopic dermatitis, fueling strong investor interest.Top-line alopecia areata data is due in December 2025, with the FDA Fast Track status adding momentum.Shares of Nektar Therapeutics (NKTR) have rallied 38.2% in the past week due to growing investor optimism related to the company’s lead pipeline candidate, rezpegaldesleukin (rezpeg), which is being ...